GUTSFractyl Health, Inc.
$1.08-93% 1Y
$1.08
$1.0852 weeks$28.44
Latest close: a new 52-week lowOct 23, 2026what changed →
Price
-93%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for GUTS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market valuen/a
1 year-93%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $0 (−100% year on year) and net income −$141M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 22, 2026On October 21, 2026, Fractyl Health, Inc. (the “Company”) adopted a plan to sharpen its strategic focus on its Revita ® program in connection with a strategic reprioritization.Exit or disposal costs (restructuring) · Form 8-K
- Oct 16, 2026On October 16, 2026, the Company reported topline six-month results from its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled pivotal study evaluating the safety and efficacy of Revita in maintaining weight loss after GLP-1 based therapy discontinuation.Regulation FD disclosure · Form 8-K
- Oct 1, 2026On September 30, 2026, Fractyl Health, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split (the “Reverse Stock Split”) of its …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry